

Barcelona, November 14th 2017

SIGNIFICANT EVENT

Pipeline update

Almirall, S.A. (“Almirall”), pursuant to article 17 of Regulation (EU) No. 596/2014 on market abuse and article 228 of the restated text of the Securities Market Act approved by the Royal Legislative Decree 4/2015, of 23 October and related provisions, hereby announces that:

The anticipated approval for tildrakizumab and its launch in European markets are moved from mid-2018 to end of 2018 or early 2019. This follows a communication received from European Medicines Agency (EMA), which is extending the scope of the clinical sites under review.

We continue to believe in tildrakizumab potential and we will provide an update of our R&D pipeline together with the Full Year 2017 financial results presentation.

Almirall announced an agreement with Sun Pharma on July 27th 2016 to in-licence tildrakizumab in Europe, as well as the right of first negotiation to extend the licence for other indications within Dermatology and Rheumatology.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com